The IMF trims its economic growth forecast again as the U.S.-China trade war continues, Brexit worries linger and inflation remains muted.Economyread more
Citigroup thinks Tesla investors hoping for a post-earnings rally later this week should scrutinize a pair of related financial metrics.Investingread more
Olive branches were extended from both China and the U.S. as the two nations are set to restart face-to-face trade negotiations after a monthlong truce.Marketsread more
Coca-Cola topped Wall Street's expectations for earnings and revenue.Food & Beverageread more
New disclosures show Facebook and Amazon each spent more than $4 million on lobbying activity in the second quarter of 2019.Technologyread more
Boris Johnson, one of the biggest voices in the Brexit movement, wins the Conservative Party leadership race by a 2-1 margin.Europe Politicsread more
Disney can nearly double its earnings by 2024, Morgan Stanley said in a note to clients on Tuesday.Investingread more
Amazon is expected to report its second-quarter earnings on Thursday.Investingread more
The largest residential brokerage company in the U.S. is partnering with the largest online retailer in a strategy to boost sales for both.Real Estateread more
Here are the biggest calls on Wall Street on TuesdayInvestingread more
Canaccord Genuity's Tony Dwyer believes stocks are about to fall as much as 5% from their all-time highs.Trading Nationread more
All good things must come to an end. Cramer says it's time to ring the register on this stock, if you own it.
And owning Valeant Pharma has been a good thing. Over the past 5 years shares have surged over 1000%.
Nonetheless Cramer thinks it's time to sell. "And stay away from the stock if you don't own it," he added.
The Mad Money host arrived at this conclusion after poring over an article written by CNBC contributor Herb Greenberg for TheStreet.
"When Herb Greenberg throws a red flag, I pay attention. His track record is just too good," Cramer said. And in the case of Valeant, Greenberg is throwing flags here, there and everywhere.
Greenberg's concerns largely stem from the goals and growth strategy set forth by Valeant CEO Michael Peason.
"When Peason took over back in 2008, he said Valeant's high-aspiration goal was to become one of the top 15 pharma companies by the end of 2013," Cramer noted
Peason achieved that goal. However, he did it through a string of . "They have done sixty deals in the last six years," Cramer noted.
However, what worries Greenberg is that the company now has a new aspirational target.
"Valeant wants to be among the top five pharma companies by the end of 2016, which would mean more than tripling the company's market cap over the next three years to $150 billion. That is a very ambitious goal, and Herb Greenberg makes it pretty clear that the only way Valeant can even get near there is by doing many more acquisitions, and possibly one big acquisition."
Historically, Greenberg says this is the kind of strategy that almost always ends badly. That is, the deals either dry up or they're not as accretive as they once were or they burden the company with massive debt.
In fact, the acquisition strategy has already generated a lot of debt.
"Herb points out that the company's debt has ballooned from $4.9 billion two years ago up to $17 billion as of last quarter." Even more debt on the balance sheet can't be good.
To make this strategy all the more concerning, Greenberg reminds that interest rates are rising. "Higher rates make it much more expensive for Valeant to borrow the money it needs to do these deals," Cramer said.
And Greenberg notes that M&A in the sector is accelerating broadly. That likely makes future acquisitions more expensive. Again, a problem.
Read More from Mad Money with Jim Cramer
Major market changes happening overnight
Do you need a stiff drink?
10 themes developing in the market right now
On top of all that, if the company issues a secondary to pay for the expansion, shareholders will likely be facing significant dilution. That's not good, either.
All told, Greenberg's analysis suggests owning Valeant going forward might be something like a game of hot potato. "When the deals eventually dry up, you do not want to be the one holding this stock."
Cramer agrees with Greenberg. "Even if we end up sitting out a lot of upside in the near-term, I'm telling you, it's just not worth the risk," Cramer said. "I've followed Herb's work for more than 20 years and I never want to be on the wrong side of one of his challenges."
Call Cramer: 1-800-743-CNBC
Questions for Cramer? firstname.lastname@example.org
Questions, comments, suggestions for the "Mad Money" website? email@example.com